Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class

International Journal of Clinical Practice

Volumn 70, Issue 1, 2016, Pages 45-55

  Blak, B T ^a   Rigney, U ^a   Sternhufvud, C ^b   Davis, J ^a   Hammar, N ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; ENGLISHMAN; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; ECONOMICS; MIDDLE AGED; PRIMARY HEALTH CARE; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; UTILIZATION;

DIABETES MELLITUS, TYPE 2; DRUG PRESCRIPTIONS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; UNITED KINGDOM; WEIGHT GAIN; WEIGHT LOSS;

EID: 84955388495     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12746     Document Type: Article

References (32)

1. Diabetes UK. Diabetes Facts and Stats. Version 3, March 2014. www.diabetes.org.uk/Documents/About%20Us/Statistics/Diabetes-key-stats-guidelines-April2014.pdf (accessed August 2014).
2. International Diabetes Federation. Diabetes: facts and figures. 2013. www.idf.org/worlddiabetesday/toolkit/gp/facts-figures (accessed August 2014).
3. Hex N, Bartlett C, Wright D, et al., Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012; 29: 855-62.
4. Brandle M, Zhou H, Smith BR, et al., The direct medical cost of type 2 diabetes. Diabetes Care 2003; 26: 2300-4.
5. Yu AP, Wu EQ, Birnbaum HG, et al., Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007; 23: 2157-69.
6. National Diabetes Audit 2011-2012. Report 1: care processes and treatment targets. Health and Social Care Information Centre, 2013.
7. Meneghini LF, Orozco-Beltran D, Khunti K, et al., Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 3337-53.
8. Brooks AM, Thacker SM,. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2009; 43: 1286-93.
9. McAdam-Marx C, Mukherjee J, Bellows BK, et al., Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Clin Pract 2014; 103: 402-11.
10. Grandy S, Fox KM, Hardy E,. Medication adherence among adults with type 2 diabetes mellitus who lost vs. gained weight. Diabetes 2013; 62 (Suppl. 1): 2926-PO.
11. Feldstein AC, Nichols GA, Smith DH, et al., Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008; 31: 1960-5.
12. Grandy S, Fox KM, Bazata DD,. Association of self-reported weight change and quality of life, and exercise and weight management behaviors among adults with type 2 diabetes mellitus: the SHIELD Study. Cardiol Res Pract 2012; 2012: 892564. doi: 10.1155/2012/892564.
13. Look AHEAD Research Group;, Wing RR,. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-75.
14. Williamson DF, Thompson TJ, Thun M, et al., Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-504.
15. Davis WA, Bruce DG, Davis TME,. Economic impact of moderate weight loss in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabet Med 2011; 28: 1131-5.
16. Wolf AM, Conaway MR, Crowther JQ, et al., Translating lifestyle intervention to practice in obese patients with type 2 diabetes: improving control with activity and nutrition (ICAN) study. Diabetes Care 2004; 27: 1570-6.
17. Williams T, van Staa T, Puri S, et al., Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012; 3: 89-99.
18. Herrett E, Thomas SL, Schoonen WM, et al., Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
19. Quality and Outcomes Framework (QOF) Business rules v24.0. Primary Care Commissioning (PCC), 26 November 2012. http://www.pcc-cic.org.uk/article/qof-business-rules-v240 (accessed September 2013).
20. Curtis L,. Unit costs of health and social care. Personal Social Services Research Unit. 2012. http://www.pssru.ac.uk/project-pages/unit-costs/2012/index.php?file=full (accessed August 2014).
21. National Schedule of Reference Costs-Year 2011-12-NHS trusts and NHS foundation trusts. Table: Direct Access: Pathology Services. https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012 (accessed November 2013).
22. The National Health Service (NHS) Business Services Authority Drug Tariff. August 2013. www.nhsbsa.nhs.uk/924.aspx (accessed August 2013).
23. Townsend P, Phillimore P, Beattie A,. The Approach. Health and Deprivation: Inequality and the North. London: Routledge, 1988: 3-38.
24. Pregibon D,. Goodness of link tests for generalized linear models. J Roy Statist Soc Ser C (Appl. Stat.) 1980; 29: 15-24.
25. Sapra S,. A regression error specification test (RESET) for generalized linear models. Econ Bull 2005; 3: 1-6.
26. Carruthers E, Lewis K, McCue T, et al., Generalized linear models: model selection, diagnostics, and overdispersion. Memorial University of Newfoundland, 4 March, 2008. http://www.mun.ca/biology/dschneider/b7932/B7932Final4Mar2008.pdf/ (accessed June 2014).
27. Bell K, Parasuraman S, Shah M, et al., Economic implications of weight change in patients with type 2 diabetes mellitus. Am J Manag Care 2014; 20: e320-9.
28. Rodbard HW, Fox KM, Grandy S,; Shield Study Group. Impact of obesity on work productivity and role disability in individuals with and at risk for diabetes mellitus. Am J Health Promot 2009; 23: 353-60.
29. Green AJ, Bazata DD, Fox KM, Grandy S,. Quality of life, depression, and healthcare resource utilization among adults with type 2 diabetes mellitus and concomitant hypertension and obesity: a prospective survey. Cardiol Res Pract 2012; 2012: 404107. doi: 10.1155/2012/404107.
30. Ridderstråle M, Gudbjörnsdottir S, Eliasson B, et al., Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 2006; 259: 314-22.
31. Vietri V, Isherwood G, Le Pautremat V, et al., Obesity and frequent hypoglycemia in European type 2 diabetes patients. ISPOR 15th Annual European Conference, 3-7 November 2012. Berlin, Germany. PDB73.
32. Tobias DK, Pan A, Jackson CL, et al., Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med 2014; 370: 233-44.